SEC Tracker
Get the app

TriSalus Life Sciences TLSI

TriSalus Life Sciences reported a net loss of $8.85 million

TriSalus Life Sciences (TLSI) filed a 10-Q with the SEC on Nov 10, 2026, 8:09 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $12.88 million for the three months ended Sep 30, 2026
  2. Net loss: $8.85 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $41.06 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when TriSalus Life Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$12.88M$11.41M+13%
Operating income and margin−$7.71M · -59.9%−$9.81M · -86%+21%, margin +26.1 pts
Net income−$8.85M−$9.19M+3.6%
Operating cash flow−$5.28M−$10.13M+48%
Cash$41.06M$46.29M−11%

Data on this page was fetched . The filing on SEC.gov is the record.